DC Vaccination for Post-remission Therapy in AML

NCT ID: NCT02405338

Last Updated: 2020-07-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2019-11-30

Brief Summary

This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients.

Trial subjects will receive repeated immunotherapies with autologous Dendritic Cells (DCs), presenting two leukemia-associated antigens.

Detailed Description

20 patients with AML who are in remission (ELN criteria by Döhner et al 2017) receive WT1/PRAME autologous DC vaccine by intradermal injection once per week during the first 4 weeks and 1 per month thereafter for 23 consecutive months.

Primary objective is to assess the safety and tolerability of the DC vaccine in the aforementioned population and the feasibility.

Secondary objectives include evaluation of clinical response and exploratory immune monitoring assessments.

Conditions

Acute Myeloid Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

WT1/PRAME vaccination

Group Type: EXPERIMENTAL

WT1/PRAME vaccination

Intervention Type: BIOLOGICAL

Interventions

WT1/PRAME vaccination

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Diagnosis of Acute Myeloid Leukemia (AML)
• Age 18 - 75 years
• Morphologic remission (CR) with or without hematological recovery (CRi) following induction chemotherapy
• WT1 with or without PRAME positivity by qPCR
• Negative pregnancy test in women of childbearing potential (within 7 days before the first vaccination). Women of childbearing potential and sexually active male participants must use reliable methods of contraception during the whole treatment period and 3 months after the last trial drug dose
• Negative HIV 1 and 2 test, Hepatitis B and C test and negative Syphilis test at screening
• Informed consent signed prior to any trial related activities

Exclusion Criteria

• Patients suitable for allogeneic stem cell transplantation
• AML M3 (acute promyelocytic leukemia)
• Patients not in complete remission (CR or CRi), bone marrow blast count ≥ 5 %
• Active immunodeficiency syndromes
• Concurrent active second malignancy other than non-melanoma skin cancers
• Clinically relevant autoimmune disease
• Prior immunotherapy
• Severe organ dysfunction precluding the apheresis procedure:
• Creatinine > 200 mmol/l
• Bilirubin, ALAT and ASAT > 3 x upper normal limit
• Respiratory insufficiency with pO2 < 60 mmHg
• Clinically relevant coronary heart disease of ventricular arrhythmia, congestive heart failure > grade II NYHA
• Recent cerebral hemorrhage
• Known allergies to substances used in the generation of DCs
• Other severe acute or chronic medical psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or the administration of the investigational product
• Use of corticosteroids
• Active CMV infection (Antibody-positivity due to previous, now inactive infection is accepted)
• Inability to comply with the trial protocol
• Participation in other clinical trials that, according to the investigator's discretion, may interfere with this trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medigene AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yngvar Fløisand

Role: PRINCIPAL_INVESTIGATOR

Oslo University Hospital, Rikshospitalet Department of Hematology

Locations

Oslo University Hospital, Rikshospitalet

Oslo, , Norway

Countries

Norway

Other Identifiers

CD-FDC-001

Identifier Type: -

Identifier Source: org_study_id